UPSC Darpan

Health & Life SciencesGS2 · GS39 October 2026

Centre to cap trade margins at 30% on non-scheduled cancer drugs after NPPA finds 170% mark-ups

Open in the app — quiz, notes, Mistake Vault हिंदी में पढ़ें

The news

New Delhi. The Union government will cap trade margins at 30% of the maximum retail price (MRP) on non-scheduled anti-cancer drugs, The Hindu and The Indian Express report. A trade margin is the gap between the price a distributor pays the manufacturer and the MRP the patient pays. The Express counts 110 drugs, 35 patented; The Hindu says “all” such drugs, the list to be finalised by a committee under the Directorate General of Health Services. Branded and generic, domestic and imported, patented and non-patented medicines are covered. The National Pharmaceutical Pricing Authority (NPPA) found average trade mark-ups of about 170%, up to 700% in some cases. The Express adds that it may take effect within about 10 days, cutting some prices by up to 70%.

The chain in one line: Costly cancer drugs escape ceiling prices → the chain adds mark-ups averaging 170% → the Supreme Court calls a ₹27,000 MRP on a ₹2,700 drug “carnage” → NPPA data quantifies the gap → the Centre caps margins at 30%

Static syllabus linkage

  1. The DPCO, 2013 fixes prices only for scheduled drugs. The Drugs (Prices Control) Order, 2013 is issued under the Essential Commodities Act, 1955. Medicines in the National List of Essential Medicines (NLEM) are scheduled, and the NPPA fixes a ceiling price for them. For all other, non-scheduled drugs the company sets the price and may raise the MRP by no more than 10% a year.
  2. The NPPA can also cap trade margins. The NPPA, set up in 1997, enforces the DPCO under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers. A margin cap leaves the factory price free and limits what the chain adds. Its 2019 cap of 30% on 42 cancer drugs used the DPCO’s power to act in extraordinary circumstances (Down To Earth); MRPs fell by up to 91% (Express).

Why UPSC loves this

  1. Medicine prices are the core of the GS2 health line. The syllabus asks about “Social Sector/Services relating to Health”. Out-of-pocket spending on drugs is its sharpest example.

Prelims nuggets

  • The Drugs (Prices Control) Order, 2013 is issued under the Essential Commodities Act, 1955 and enforced by the NPPA.
  • Scheduled formulations under the DPCO are the medicines in the National List of Essential Medicines.
  • A manufacturer may raise the MRP of a non-scheduled formulation by at most 10% a year.

Analysis

  1. The cap hits the chain, not the inventor — its strength and its gap. Because the manufacturer’s price to the distributor is untouched, patented launches are not discouraged. Officials chose only expensive drugs, since 30% on a cheap drug would not cover marketing costs. The gap: a firm can raise its price to the distributor and keep the old MRP, so the NPPA must watch factory prices too.
  2. Price caps treat the symptom; marketing creates the mark-up. Margins are large because the doctor, not the patient, picks the brand. On October 8 a Bench of Justices Vikram Nath and Sandeep Mehta, on a PIL by medical representatives’ unions, directed the Centre to form a committee within two weeks on a statutory regime against unethical marketing, as the voluntary 2015 code is ineffective. Without that law, squeezed margins may return as incentives.
  3. Lens — Market and State: a cancer patient cannot shop, so the State sets the boundary. The NPPA found sharp price gaps between retail outlets, hospitals and online pharmacies — the mark of a captive buyer. Intervention is justified, but heavy controls can delay launches. A sensible officer caps the chain and watches stock-outs first.

Possible Mains question

Trade margin rationalisation is a lighter touch than price control. Examine its potential to make cancer medicines affordable in India. (15 marks, 250 words)

Model approach

  1. Directive — Examine. Probe how the cap works and can be evaded, then judge.
  2. Introduction — the 170% finding and the 30% cap. Define trade margin in one line.
  3. Body — it targets the captive buyer without touching the inventor. Value addition: the 2019 cap cut MRPs by up to 91%. Draw factory → distributor → hospital or retailer → patient, marking the 30% cap.
  4. Body — higher factory prices and stock-outs are the evasion risk. Monitoring must accompany the cap.
  5. Body — marketing reform must follow. Cite the Supreme Court’s October 8 committee order.
  6. Conclusion — a cap is a first step. Pair it with enforceable marketing law and generic supply.

Administrator's brainstorm

You are a State Drugs Controller. Hospital pharmacies now call the capped drugs “out of stock”. What do you do?

I would verify through test purchases and stock registers, since false stock-outs push patients to costlier substitutes. Withheld stock or overcharging goes to the NPPA for recovery. I would display the capped MRPs and a helpline at every hospital pharmacy.